Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 307 results found since Jan 2013.
HPS2-THRIVE Coming Attraction: First Look At What Went Wrong With Niacin
In a few weeks, on March 9, the main results of the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study will be presented in San Francisco at the annual meeting of the American College of Cardiology. These results have been eagerly awaited since Merck’s brief announcement in December that the trial had not met its primary endpoint and that it would no longer pursue approval of Tredaptive, the combination of extended-release niacin and laropiprant, in the US. The trial was designed to assess whether adding the niacin/laropiprant combination to standard st...
Source: CardioBrief - February 27, 2013 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes European Heart Journal High-density lipoprotein Laropiprant Merck niacin Statin Tredaptive Source Type: blogs
Are Most People With Complex Coronary Disease Getting The Best Treatment?
The relative value of PCI (stents) and bypass surgery for the treatment of people with blocked coronary arteries has been a topic of intense interest and debate for more than a generation now. Over time, the less invasive and more patient-friendly (and less scary) PCI has become the more popular procedure, but the surgeons (who perform bypass surgery) and cardiologists (who perform the less invasive PCI) have argued furiously about which procedure is safest and will deliver the most benefit in specific patient populations. In general, the most complex cases require the more thorough revascularization More…
Source: CardioBrief - February 22, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Coronary artery bypass surgery Heart disease Lancet multivessel disease PCI stents Source Type: blogs
Small Study Explores Expanded Use For TAVI In Native Valve Aortic Regurgitation
As transcatheter aortic valve implantation (TAVI) gains increasing acceptance, cardiologists and surgeons are exploring additional patient populations who may benefit from the procedure. A new paper in the Journal of the American College of Cardiology provides the first look at the use of TAVI in the small but important group of patients with pure, severe native aortic valve regurgitation (NAVR) who do not have aortic stenosis. … The authors acknowledge that TAVI will likely be used sparingly in the NAVR population: …although these results are encouraging for those patients who are truly ineligible for surger...
Source: CardioBrief - February 20, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Aortic valve Aortic valve stenosis Medtronic TAVI transcatheter aortic valve replacement Source Type: blogs
400 Patients Sue Kentucky Hospital and 11 Cardiologists Over Unnecessary Procedures
After undergoing more than two dozen cardiac procedures over a period of twenty years at St. Joseph Hospital in London, Kentucky, a patient was told by an outside cardiologist in Lexington that a recent procedure had been performed unnecessarily on an artery that was barely blocked. “I would have not carried out this procedure,” the cardiologist, Michael R. Jones, wrote in a letter to the patient. The story is recounted in an article published on Sunday in USA Today and the Louisville Courier-Journal, about the latest and perhaps the biggest case yet to surface over unnecessary cardiac procedures. More…
Source: CardioBrief - February 17, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics Catholic Health Initiatives Mark Midei New York Times st joseph medical center United States Department of Justice unnecessary stents Source Type: blogs
St. Jude Raises The Stakes In Renal Denervation With An Outcomes Study
The already hot field of renal denervation for resistant hypertension just got a little hotter. With the announcement of a clinical trial powered to detect improvements in cardiovascular outcomes, St. Jude Medical has raised the stakes. … “To date, the renal denervation studies that have been conducted only looked at reducing blood pressure in patients with uncontrolled or resistant hypertension,” said Michael Böhm, a principal investigator for the trial, in a St. Jude press release. “What we need to know is if this minimally invasive approach for treating hypertension also correlates to a reduction More…
Source: CardioBrief - February 15, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes hypertension renal denervation Source Type: blogs
ACC And STS Break New Ground To Test TAVR For Unapproved Uses
In a startling break with tradition, the American College of Cardiology and the Society of Thoracic Surgeons will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR). The two medical groups have recently been granted an investigational device exemption (IDE) by the FDA for one such trial and hope to gain an IDE for at least two more trials. The news was first reported by The Gray Sheet (subscription required) on February 8. The new development represents a significant enlargement of the TVT registry, already run by the ACC and STS, More…
Source: CardioBrief - February 12, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery ACC Aortic valve CMS Edwards FDA food and drug administration IDE Medicare Sapien STS TAVR Source Type: blogs
Should Radial Artery Access Be The Default Choice For PCI?
Over on CardioExchange six cardiologists, from fellows to senior faculty, talk about whether radial artery access should be the “default choice for PCI: Megan Coylewright, MD, MPH (interventional fellow, Mayo Clinic): …radial PCI should be a part of every interventionalist’s toolkit… Micah Eimer, MD (cardiologist, Glenview, IL): The data are pretty convincing on the lower rate of complications, and my clinicial experience confirms that. Patients who have undergone both radial and femoral approaches consistently and strongly prefer the radial approach… L. David Hillis, MD, (Chair, Department of I...
Source: CardioBrief - February 7, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Conventional PCI femoral access radial access Source Type: blogs
Large Study Finds Genetic Links To Aortic Valve Calcification
A genetic component is believed to play an important role in valvular heart disease, but the specific genes involved have not been identified. Now an interntional group of researchers has identified genetic variations that increase the risk for valvular calcification. In a paper published in the New England Journal of Medicine, members of the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium report on their search for genes associated with aortic valve calcification and mitral annular calcification in several of study cohorts. They found one SNP, in a gene previously shown to be associated with More…
Source: CardioBrief - February 6, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes Aortic valve Calcification coronary artery disease Gene health Heart disease Source Type: blogs
Should Physicians Be Business Partners With Medical Device Salesmen?
Should a Florida cardiologist co-own a business running frozen yogurt shops with a medical device salesman? That’s the question raised by reporter John Dorschner in a story posted by the Miami Herald yesterday: “Mark Sabbota, a Hollywood cardiologist, regularly implants $5,000 pacemakers in patients at Memorial hospitals in South Broward — generating, last year alone, more than a half-million dollars in sales for a manufacturer called St. Jude Medical. Sabbota, public records show, also happens to be partners with a St. Jude sales rep in two corporations that run frozen yogurt shops.” Click here More…
Source: CardioBrief - February 3, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Interventional Cardiology & Surgery People, Places & Events Policy & Ethics AdvaMed device saleman medical ethics Miami Herald Sabbota st jude medical Source Type: blogs
European Heart Journal Retracts Main Paper Of The Kyoto Heart Study
This article has been retracted by the journal. Critical problems existed with some of the data reported in the above paper. The editors of the European Heart Journal hereby retract this paper and discourage citations of More…
Source: CardioBrief - February 2, 2013 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics European Heart Journal European Society of Cardiology Kyoto Heart Study scientific misconduct Source Type: blogs
Whistleblower Lawsuit Yields $2.4 Million For New Jersey Cardiologist
A New Jersey cardiologist will receive $2.4 million for his role in a whistleblower lawsuit against Cooper Health System and Cooper University Hospital. Following an investigation by the US Department of Justice and the New Jersey Attorney General’s Office, Cooper agreed last week to pay $12.6 million to settle Medicare and Medicaid fraud allegations. The federal qui tam lawsuit was originally filed by Delaware Valley cardiologist Nicholas L. DePace, who claimed that Cooper paid illegal kickbacks to physicians for patient referrals. Click here to read the full story on Forbes.
Source: CardioBrief - January 31, 2013 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Source Type: blogs
Small Study Suggests Yoga May Benefit AF Patients
A small study published online in the Journal of the American College of Cardiology suggests that yoga may benefit people who have atrial fibrillation. The study, which the authors describe as “a small, proof-of-concept study,” is the first of its kind. The findings raise the possibility that yoga may reduce AF symptoms and arrhythmia burden. Other physiological and quality of life benefits were also observed. But, the authors caution, large randomized trials will be required to confirm the finding. Click here to read the full post on Forbes.
Source: CardioBrief - January 30, 2013 Category: Cardiology Authors: Larry Husten Tags: Uncategorized alternative medicine atrial fibrillation complementary medicine yoga Source Type: blogs
ESC Gives A Shot In the Arm To Radial Access For PCI Procedures: The New Default?
Radial access is now the preferred approach for percutaneous coronary interventions, according to a consensus document from the European Society of Cardiology and other European organizations and published online in EuroIntervention. However, at least one prominent US interventional cardiologist thinks the “hard benefits” of radial access “are more controversial,” though he supports increased use of the newer approach. Click here to read the full story on Forbes.
Source: CardioBrief - January 28, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery femoral artery Percutaneous coronary intervention Radial artery Source Type: blogs
Renal Denervation: Delineating Its Uses, Misuses, and Possibilities
Over on CardioExchange, Murray Essler, the chief investigator of the Symplicity HTN-2 trial, answers questions from John Ryan about renal denervation: Non-pharmacologic antihypertensive measures must remain the starting point for patients with hypertension, but will often not be enough. Renal denervation should be reserved for patients in whom behavior modification combined with adequate and skillful antihypertensive drug prescribing cannot achieve BP reduction to target. There are no clinical trial data to support renal denervation in hypertension outside of this setting. In countries where the “genie is out of t...
Source: CardioBrief - January 22, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes hypertension renal denervation resistant hypertension Source Type: blogs
Trials Of Niacin And Atrial Fibrillation Device Will Headline American College Of Cardiology Program
Two big trials will highlight this year’s American College of Cardiology meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific‘s long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation. Second is the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. Read my complete story on Forbes, along with a list of the late-breakers.
Source: CardioBrief - January 22, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Heart Rhythms Interventional Cardiology & Surgery MI/ACS People, Places & Events American College of Cardiology atrial fibrillation Boston Scientific niacin San Francisco Watchman Source Type: blogs
